OncoMatch/Clinical Trials/NCT07057427
Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
Is NCT07057427 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Nab paclitaxel and Docetaxel and Carboplatin for breast cancer.
Treatment: Nab paclitaxel · Docetaxel and Carboplatin · Trastuzumab + Pertuzumab — The aim of this study is to evaluate the efficacy of nab-paclitaxel (on days 1 and 8 of a 21-day cycle) compared to the standard regimen of docetaxel plus carboplatin, both combined with trastuzumab and pertuzumab, as neoadjuvant therapies for HER2-positive breast cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression (ihc 3+ or fish positive)
Disease stage
Required: Stage T4C, T4D, T1C WITH AXILLARY LYMPH NODE POSITIVITY (AJCC TNM)
Excluded: Stage IV
Clinical Tumor Stage: T2-T4d, or T1c with axillary lymph node positivity. Stage IV (metastatic) breast cancer [excluded].
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic therapy
Prior systemic therapy or radiotherapy for the current breast cancer diagnosis, including chemotherapy, endocrine therapy, or targeted therapy
Cannot have received: radiation therapy
Prior systemic therapy or radiotherapy for the current breast cancer diagnosis, including chemotherapy, endocrine therapy, or targeted therapy
Lab requirements
Blood counts
ANC ≥ 2.0 × 10⁹/L; Hemoglobin ≥ 100 g/L; Platelet count ≥ 100 × 10⁹/L
Kidney function
Serum creatinine < 1.5 × ULN
Liver function
Total bilirubin < 1.5 × ULN; AST/ALT < 1.5 × ULN
Cardiac function
LVEF ≥ 55% assessed by echocardiography
Adequate organ and bone marrow function within 1 month prior to chemotherapy initiation (no contraindications to chemotherapy): 1. Absolute neutrophil count (ANC) ≥ 2.0 × 10⁹/L 2. Hemoglobin ≥ 100 g/L 3. Platelet count ≥ 100 × 10⁹/L 4. Total bilirubin < 1.5 × ULN 5. Serum creatinine < 1.5 × ULN 6. AST/ALT < 1.5 × ULN. Cardiac function: LVEF ≥ 55% assessed by echocardiography.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07057427 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ERBB2?
Yes, ERBB2 overexpression is a required biomarker for enrollment.
What disease stage is eligible?
Stage T4C or T4D or T1C WITH AXILLARY LYMPH NODE POSITIVITY is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages